Does the Dose Matter?
Open Access
- 15 September 2001
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 33 (s3), S233-S237
- https://doi.org/10.1086/321854
Abstract
Pharmacokinetic/pharmacodynamic (PK/PD) parameters, such as the ratio of peak to minimum inhibitory concentration (peak/MIC ratio), ratio of 24-hour area under the curve to MIC (24-h AUC/MIC ratio), and the time above MIC, are good indicators of the drug dose—organism interaction. Time above the MIC is the important determinant of the activity of β-lactams, macrolides, clindamycin, and linezolid. Free drug serum levels of these drugs should be above the MIC for at least 40%–50% of the dosing interval to produce adequate clinical and microbiological efficacy. Peak/MIC and 24-h AUC/MIC ratios are major determinants of the activity of aminoglycosides and fluoroquinolones. In general, peak/MIC ratios should exceed 8 and 24-h AUC/MIC values should be >100 to successfully treat gram-negative bacillary infections and to prevent the emergence of resistant organisms during therapy. The successful treatment of pneumococcal infections with fluoroquinolones and azithromycin appear to require 24-h AUC/MIC ratios of only 25–35. Mutation prevention concentrations are being reported for various fluoroquinolones with different pathogens, but their clinical significance has not yet been established. More information is needed on the role of PK/PD parameters and their magnitude for preventing mutations and the emergence of resistant organisms for most classes of antibiotics.Keywords
This publication has 22 references indexed in Scilit:
- State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and MenClinical Infectious Diseases, 1998
- Pharmacokinetics and pharmacodynamics of antibiotics in otitis media*The Pediatric Infectious Disease Journal, 1996
- Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporinsDiagnostic Microbiology and Infectious Disease, 1995
- Pharmacodynamics of intravenous ciprofloxacin in seriously ill patientsAntimicrobial Agents and Chemotherapy, 1993
- Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsisAntimicrobial Agents and Chemotherapy, 1993
- Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infectionsJournal of Antimicrobial Chemotherapy, 1991
- Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections. Impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradicationArchives of Internal Medicine, 1989
- Comparative Antibiotic Dose-Effect Relations at Several Dosing Intervals in Murine Pneumonitis and Thigh-Infection ModelsThe Journal of Infectious Diseases, 1989
- Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal ModelThe Journal of Infectious Diseases, 1988
- Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistanceAntimicrobial Agents and Chemotherapy, 1987